Novel Treatments for Pediatric Relapsed or Refractory Acute B-Cell Lineage Lymphoblastic Leukemia: Precision Medicine Era

Mengxuan, Shang; Zhou, Fen; Jin, Runming

doi:10.3389/fped.2022.923419

Cited by 12 publications

(6 citation statements)

References 174 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Future studies with these B cell-specific aptamers could potentially yield safer and more efficacious treatments for B-ALL. 81 , 82 …”

Section: Discussionmentioning

confidence: 99%

Selection of a novel cell-internalizing RNA aptamer specific for CD22 antigen in B cell acute lymphoblastic leukemia

Ruiz-Ciancio,

Lin,

Veeramani

et al. 2023

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

“…Future studies with these B cell-specific aptamers could potentially yield safer and more efficacious treatments for B-ALL. 81 , 82 …”

Section: Discussionmentioning

confidence: 99%

Selection of a novel cell-internalizing RNA aptamer specific for CD22 antigen in B cell acute lymphoblastic leukemia

Ruiz-Ciancio,

Lin,

Veeramani

et al. 2023

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

“…T-cell activation requires the engagement of the endogenous T-cell receptor (TCR) by its cognate peptide/major histocompatibility complex (MHC) [ 4 ]. Activated T-cells will then be directed against lymphoblastic B-cells expressing several targets [ 5 ]. CAR T-cell is classified into five different generation based on their intracellular signalling domain, which may include CD3 zeta (CD3ζ) [1st generation], plus a costimulatory domain (4-1BB or CD28) to enhance T-cell activation [2nd generation] or multiple costimulatory domains (4-1BB or CD28, CD134 or CD137) [3rd generation].…”

Section: Introductionmentioning

confidence: 99%

Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: a systematic review and meta-analysis

Willyanto,

Alimsjah,

Tanjaya

et al. 2024

Annals of Medicine

View full text Add to dashboard Cite

Background Relapse/refractory B-cell acute lymphoblastic leukaemia (r/r B-ALL) represents paediatric cancer with a challenging prognosis. CAR T-cell treatment, considered an advanced treatment, remains controversial due to high relapse rates and adverse events. This study assessed the efficacy and safety of CAR T-cell therapy for r/r B-ALL. Methods The literature search was performed on four databases. Efficacy parameters included minimal residual disease negative complete remission (MRD-CR) and relapse rate (RR). Safety parameters constituted cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Results Anti-CD22 showed superior efficacy with the highest MRD-CR event rate and lowest RR, compared to anti-CD19. Combining CAR T-cell therapy with haploidentical stem cell transplantation improved RR. Safety-wise, bispecific anti-CD19/22 had the lowest CRS rate, and anti-CD22 showed the fewest ICANS. Analysis of the costimulatory receptors showed that adding CD28ζ to anti-CD19 CAR T-cell demonstrated superior efficacy in reducing relapses with favorable safety profiles. Conclusion Choosing a more efficacious and safer CAR T-cell treatment is crucial for improving overall survival in acute leukaemia. Beyond the promising anti-CD22 CAR T-cell, exploring costimulatory domains and new CD targets could enhance treatment effectiveness for r/r B-ALL.

show abstract

“…Следует отметить, что, несмотря на относительно невысокую интенсивность международных про-girls and 25 (47 %) boys with median age of 7,7 (2,(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)8) years. Indications for using of BM were as follows: (1) consolidation of remission (CR) with primary ALL (n = 17, 32 %);…”

Section: Introductionunclassified

Blinatumomab in pediatric acute lymphoblastic leukemia: one center experience

Muliarova,

Smirnova,

Lapaeva

et al. 2024

jour

View full text Add to dashboard Cite

Background. Despite the successes achieved in the treatment of B-cell acute lymphoblastic leukemia (B-ALL), overcoming the toxicity of standard chemotherapy regimens and the treatment of relapsed/refractory (r/r) forms of the disease remains relevant. The most promising option is to use immunotherapy (IT), including a monoclonal antibody blinatumomab (BM). The purpose of the study. To analyze indications of using, as well as efficacy and tolerability of BM in children with V-ALL. Materials and methods. From April 2016 to January 2024 a retrospective assessment of using of BM in children with B-ALL in the chemotherapy department of oncohematological diseases and TCM for children in Almazov National Medical Research Centre was performed. Results. The study included 53 patients, including 28 (53 %) girls and 25 (47 %) boys with median age of 7,7 (2,08–19,8) years. Indications for using of BM were as follows: (1) consolidation of remission (CR) with primary ALL (n = 17, 32 %); (2) persistence of minimal residual disease (MRD) (n = 23, 43 %) after completion of chemotherapy (CT) induction or before the stage of allogeneic haematopoietic stem cell transplantation (alloHSCT); (3) replacement of the standard CR due to the previous toxicity of СT or other contraindications to its implementation (n = 12, 23 %); (4) salvage therapy for r/r ALL (n = 1, 1,9 %). The status of MRD-negative remission after the 1st course of IT was achieved in 89 % of cases. Therapy using BM in a patient with the r/r ALL and total blast infiltration of the bone marrow was effective and facilitated reducing the tumor population to 7,2% by day 15 of therapy, however, there was a fatal outcome due to development and progression of preexisted severe infection. The most common variants of grade III–IV toxicity were leuko-/neutropenia (28 %) and neurotoxicity (3,7 %). BM dose reduction for the purpose of relieving toxicity was required in 19 % of patients, while the median days of therapy with dose reduction was 4. Corticosteroids were used for this purpose in 11 % of cases, antibacterial therapy — in 13 %. At the time of results evalution, there were no relapses of the disease in the study group. The article analyzes the international experience of using BM in patients with B-ALL.Conclusion. Our experience and the presented literature data demonstrate a reasonable expansion of indications for using of BM in children with B-ALL with high efficacy and satisfactory toxicity profile.

show abstract

Novel Treatments for Pediatric Relapsed or Refractory Acute B-Cell Lineage Lymphoblastic Leukemia: Precision Medicine Era

Cited by 12 publications

References 174 publications

Selection of a novel cell-internalizing RNA aptamer specific for CD22 antigen in B cell acute lymphoblastic leukemia

Selection of a novel cell-internalizing RNA aptamer specific for CD22 antigen in B cell acute lymphoblastic leukemia

Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: a systematic review and meta-analysis

Blinatumomab in pediatric acute lymphoblastic leukemia: one center experience

Contact Info

Product

Resources

About